Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study

키워드

참고문헌 (49)

1. Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
2. Yamazawa K, "A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women", Oncology, 64, pp.116~123 (2003)
3. Goldacre MJ, "Schizophrenia and cancer : an epidemiological study", Br J Psychiatry, 187, pp.334~338 (2005)
4. Lichtermann D, "Incidence of cancer among persons with schizophrenia and their relatives", Arch Gen Psychiatry, 58, pp.573~578 (2001)
5. Madhusoodanan S, "Hyperprolactinemia associated with psychotropics--a review", Hum Psychopharmacol, 25, pp.281~297 (2010)
6. Wieck A, "Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review", Br J Psychiatry, 182, pp.199~204 (2003)
7. Bostwick JR, "Antipsychotic-induced hyperprolactinemia", Pharmacotherapy, 29, pp.64~73 (2009)
8. Bushe C, "A review of the association between antipsychotic use and hyperprolactinaemia", J Psychopharmacol, 22(2 Suppl), pp.46~55 (2008)
9. 이봉주, "Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone", Clinical Psychopharmacology and Neuroscience, 11(2), pp.60~66 (2013), 대한정신약물학회
10. Alexander GC, "Increasing off-label use of antipsychotic medications in the United States, 1995-2008", Pharmacoepidemiol Drug Saf, 20, pp.177~184 (2011)
11. Leslie DL, "Off-label use of antipsychotic medications in the department of Veterans Affairs health care system", Psychiatr Serv, 60, pp.1175~1181 (2009)
12. Kaaks R, "Obesity, endogenous hormones, and endometrial cancer risk : a synthetic review", Cancer Epidemiol Biomarkers Prev, 11, pp.1531~1543 (2002)
13. Akhmedkhanov A, "Role of exogenous and endogenous hormones in endometrial cancer : review of the evidence and research perspectives", Ann N Y Acad Sci, 943, pp.296~315 (2001)
14. Dexeus S, "Hyperprolactinemia: an inductor of neoplastic changes in endometrium? A report of two cases", Gynecol Endocrinol, 12, pp.273~275 (1998)
15. Rossi AG, "Metoclopramide-induced hyperprolactinemia affects mouse endometrial morphology", Gynecol Obstet Invest, 54, pp.185~190 (2002)
16. Henderson BE, "The epidemiology of endometrial cancer in young women", Br J Cancer, 47, pp.749~756 (1983)
17. Dumesic DA, "Cancer risk and PCOS", Steroids, 78, pp.782~785 (2013)
18. Parslov M, "Risk factors among young women with endometrial cancer : a Danish case-control study", Am J Obstet Gynecol, 182(1 Pt 1), pp.23~29 (2000)
19. Brinton LA, "Reproductive, menstrual, and medical risk factors for endometrial cancer : results from a case-control study", Am J Obstet Gynecol, 167, pp.1317~1325 (1992)
20. Yavuz D, "Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women", Eur J Endocrinol, 149, pp.187~193 (2003)
21. Orbach H, "Hyperprolactinemia and autoimmune diseases", Autoimmun Rev, 6, pp.537~542 (2007)
22. Buskila D, "Autoantibody profile in the sera of women with hyperprolactinemia", J Autoimmun, 8, pp.415~424 (1995)
23. Gerli R, "Reduced number of natural killer cells in patients with pathological hyperprolactinemia", Clin Exp Immunol, 64, pp.399~406 (1986)
24. Vidaller A, "T-cell dysregulation in patients with hyperprolactinemia : effect of bromocriptine treatment", Clin Immunol Immunopathol, 38, pp.337~343 (1986)
25. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
26. Modugno F, "Inflammation and endometrial cancer : a hypothesis", Cancer Epidemiol Biomarkers Prev, 14, pp.2840~2847 (2005)
27. Dossus L, "Obesity, inflammatory markers, and endometrial cancer risk : a prospective case-control study", Endocr Relat Cancer, 17, pp.1007~1019 (2010)
28. Wallace AE, "Inflammatory events in endometrial adenocarcinoma", J Endocrinol, 206, pp.141~157 (2010)
29. Visser M, "Elevated C-reactive protein levels in overweight and obese adults", JAMA, 282, pp.2131~2135 (1999)
30. Wellen KE, "Inflammation, stress, and diabetes", J Clin Invest, 115, pp.1111~1119 (2005)
31. Pfister G, "Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective", Neuroimmunomodulation, 15, pp.351~364 (2008)
32. Cohen G, "Deprenyl suppresses the oxidant stress associated with increased dopamine turnover", Ann Neurol, 26, pp.689~690 (1989)
33. Post A, "Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells : suppression of NF-kappaB and neuroprotection by antioxidants", J Neurosci, 18, pp.8236~8246 (1998)
34. Post A, "Mechanisms underlying the protective potential of alpha-tocopherol(vitamin E)against haloperidol-associated neurotoxicity", Neuropsychopharmacology, 26, pp.397~407 (2002)
35. Sagara Y, "Induction of reactive oxygen species in neurons by haloperidol", J Neurochem, 71, pp.1002~1012 (1998)
36. Elinav E, "Inflammation-induced cancer : crosstalk between tumours, immune cells and microorganisms", Nat Rev Cancer, 13, pp.759~771 (2013)
37. Bishnoi M, "Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment : role in orofacial dyskinesia", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1473~1478 (2008)
38. Bishnoi M, "Protective effect of curcumin and its combination with piperine(bioavailability enhancer)against haloperidol-associated neurotoxicity : cellular and neurochemical evidence", Neurotox Res, 20, pp.215~225 (2011)
39. Bishnoi M, "Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia", Eur J Pharmacol, 590, pp.241~245 (2008)
40. Slomovitz BM, "The PI3K", AKT, Clin Cancer Res, pp.2012, 18[DOI]
41. Block M, "Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells", Anticancer Res, 30, pp.2025~2031 (2010)
42. Emamian ES, "Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia", Nat Genet, 36, pp.131~137 (2004)
43. Ochiel DO, "Human uterine epithelial cell secretions regulate dendritic cell differentiation and responses to TLR ligands", J Leukoc Biol, 88, pp.435~444 (2010)
44. Matsumoto A, "Haloperidol suppresses murine dendritic cell maturation and priming of the T helper 1-type immune response", Anesth Analg, 120, pp.895~902 (2015)
45. Witkiewicz AK, "Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins", Hum Pathol, 41, pp.26~32 (2010)
46. Nozaki H, "Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice", Brain Behav Immun, 10, pp.17~26 (1996)
47. Pottegård A, "Use of antipsychotics and risk of breast cancer : a Danish nationwide case-control study", Br J Clin Pharmacol, 84, pp.2152~2161 (2018)
48. Azoulay L, "The use of atypical antipsychotics and the risk of breast cancer", Breast Cancer Res Treat, 129, pp.541~548 (2011)
49. Dalton SO, "Cancer risk among users of neuroleptic medication : a population-based cohort study", Br J Cancer, 95, pp.934~939 (2006)

관련 논문AI추천